[Postmenopausal hemorrhage and endometrial cancer in tamoxifen therapy].
Report about 8 patients with endometrial pathology during tamoxifen therapy: 1 endometrial cancer, 1 adenomyosis uteri and 6 endometrial polyps. The knowledge about effects of tamoxifen on endometrium and possibilities of prevention are discussed. Sonographic screening of patients during tamoxifen therapy and if need by endometrial biopsy is necessary especially if tamoxifen is given longer than 2 years. No more than 30 mg should given in adjuvant therapy.
Krause
A
A
Universitäts-Frauenklinik Rostock.
Gerber
B
B
D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000473:pathology; D004717:Endometrium / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011127:Polyps / Q000139:chemically induced / Q000473:pathology; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D014592:Uterine Hemorrhage / Q000139:chemically induced* / Q000473:pathology
D013629:Tamoxifen
Postmenopauseblutungen und Endometriumkarzinom unter Tamoxifen-Therapie.